Skip to content

The persisting effect of episodic exercise training in patients with chronic heart failure.

The persisting effect of episodic exercise training in patients with chronic heart failure. - Exercise training in CHF patients/ PEP-HEART

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON33578
Enrollment
135
Registered
2009-06-04
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic heart failure

Interventions

12 week physiotherapist guided exercise program

Sponsors

Onze Lieve Vrouwe Gasthuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria p 10 * Symptomatic systolic heart failure (documented clinical signs and symptoms of heart failure) documented for more than 3 months. * Left ventricular ejection fraction (EF) less than 40% estimated by 2D echocardiography. * New York Heart Association (NYHA) class: II and III. * Age between 18- 80 years * Clinically stable with regard to symptoms and optimal medical therapy for more than 2 weeks prior to inclusion.

Exclusion criteria

Exclusion criteria: exclusion criteria p 11 * Orthopedic, peripheral vascular or neurological disease limiting the ability to exercise * Documented exercise-induced ischemia * Documented exercise-induced ventricular tachycardia * Poorly controlled cardiac arrhythmias * Significant chronic pulmonary disease limiting the ability to exercise * Uncontrolled hypertension * Abnormal blood pressure response to exercise testing (systolic blood pressure >250 mmHg or diastolic blood pressure >120 mmHg.) Or blood pressure drop of > 20mmHg during baseline exercise test. * Major anemia * Aortic valve stenose * Co morbidity that contraindicate exercise * Terminal disease * Patients who can*t speak/understand or read the Dutch language

Design outcomes

Primary

MeasureTime frame
Improvement of the functional capacity and to determine the prolonged effects of this intervention.

Secondary

MeasureTime frame
Secundairy endpoints are: Serum levels of NT-proBNP serum levels of CRP Quality of live (assessed with MLHFQ) Glycocalyx thickness measured with SDF. Left ventricular ejection fraction

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)